The main hypothesis of this work is that an approach combining clinical parameters and biomarker assays could improve the understanding and prediction of the occurrence of silent atrial fibrillation (AF) in the acute phase after stroke. In this prospective work, the investigators will rely on the Dijon Stroke Registry, which collects extensive clinical data for each patient hospitalized for a stroke. As part of this registry, patients are seen 6 months after stroke to assess their clinical status. This clinical follow-up will allow us to judge the evolution of the AF diagnosed during the acute episode at a distance.
Study Type
OBSERVATIONAL
Enrollment
264
2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
CHU Dijon Bourgogne
Dijon, France
Diagnosis of atrial fibrillation during continuous monitoring in a Stroke unit within six months of stroke.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.